Pancreatic Diffuse Large B-cell Lymphoma in the US Population.

Area of Science:

• Oncology
• Hematology
• Gastroenterology

Background:

• Pancreatic lymphomas (PLs) are rare, comprising <2% of all lymphomas and <0.5% of pancreatic neoplasms.
• Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of PL.
• Accurate diagnosis is crucial for prognosis and treatment of pancreatic DLBCL.

Purpose of the Study:

• To investigate demographic, clinical, and pathological factors influencing prognosis and survival in pancreatic DLBCL.
• To analyze survival rates based on treatment modalities (chemotherapy, surgery).
• To identify predictors of survival in pancreatic DLBCL patients.

Main Methods:

• Retrospective analysis of 493 pancreatic DLBCL cases from the Surveillance, Epidemiology, and End Results (SEER) database (2000-2018).
• Evaluation of demographic data, clinical presentation (localized, regional, distant involvement), and treatment received.
• Statistical analysis including survival rates and multivariable analysis to identify prognostic factors.

Main Results:

• The most affected age group was 70-79 years (27.0%).
• Distant disease involvement (44%) was common, often indicating secondary pancreatic DLBCL.
• Overall five-year survival was 46%. Survival rates were significantly higher with surgery and chemotherapy (80% at 5 years) compared to chemotherapy alone (48% at 5 years).
• Positive predictors for survival included surgery with chemotherapy. Negative predictors included age >55 years, distant stage, and no surgery.

Conclusions:

• Pancreatic DLBCL is a rare malignancy requiring timely diagnosis for effective management.
• Combined treatment with chemotherapy and surgery significantly improves survival outcomes.
• Older age and advanced disease stage are associated with poorer prognosis in pancreatic DLBCL.